A compound selected from 14-O-[((
Alkyl-, cycloalkyl-, heterocycloalkyl-, heteroaryl-, or
aryl)-
sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((
Alkyl-, cycloalkyl-, heterocycloalkyl-, heteroaryl-, or
aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first
substituent at position 12 of the mutilin ring is a
methyl group which
methyl group has the inverse
stereochemistry compared with the
stereochemistry of the
methyl group at position 12 of the naturally occurring
pleuromutilin ring, the second
substituent at position 12 of the mutilin ring is a
hydrocarbon group comprising at least one
nitrogen atom and all other substituents of the mutilin ring having the same
stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring
pleuromutilin ring; optionally in the form of a pharmaceutically acceptable salt and / or solvate,
prodrug or
metabolite, wherein the naturally occurring
pleuromutilin is of formula.for the specific use in the treatment or prevention of a
disease mediated by a
virus. The invention further relates to 12-epi-12-desvinyl-14-O-[(Piperidin-4-ylsulfanyl]-acetyl]-12-[2-(3-methyl-pyrazin-2-yl)-ethenyl]-mutilin and its therapeutic uses.